Skip to main content

In Brief This Week: Novacyt, Qiagen, Danaher, and More

NEW YORK – French diagnostics firm Novacyt said this week that private hedge fund YA II CD has notified the firm of an exercise of warrants to subscribe for 300,000 new ordinary shares at €0.946 ($1.29) per share for a total subscription of €283,000 ($365,859).   

Separately, the firm said it issued a total of almost 6.4 million new ordinary shares pursuant to the exercise of warrants. About 6 million new ordinary shares were issued to Harbert European Growth Capital Fund at €0.0698 per share for a total subscription of €420,000. Also, about 353,000 new ordinary shares were issued to Kreos Capital V at €1.45 per share for a total subscription of €512,627.  

Since Jan. 31, Novacyt has received subscriptions totalling more than €2.9 million, it said, adding it no longer has any outstanding warrants or options over ordinary shares in the issue.  

Additionally, the firm will make a net payment of €158,000 to Negma to satisfy terms of a guarantee provided to Negma related to the cancellation of 1.3 million warrants held by Negma. The guarantee was invoked by Negma on Feb. 4.  


Qiagen this week announced that Nigeria has published guidelines recommending the firm's QuantiFeron-TB Gold Plus test in screening for latent tuberculosis infection as part of the country's strategy to prevent the spread of tuberculosis. Qiagen has partnered with Nigeria’s National Tuberculosis & Leprosy Control Program to adapt World Health Organisation guidelines and provide guidance to healthcare professionals on dealing with latent TB. Nigeria is the first high-burden country to exclusively embrace modern blood tests, called interferon gamma release assays, for latent TB screening of at-risk individuals in tuberculosis control programs, Qiagen said.


Danaher this week announced a regular quarterly cash dividend of $.18 per share, payable on April 24 to shareholders of record on March 27. The company’s board of directors also approved a quarterly cash dividend of $11.785 per share of its 4.75 percent Series A Mandatory Convertible Preferred Stock, payable on April 15 to shareholders of record on March 31.


Cancer diagnostics firm VolitionRx said this week that it had $17 million in cash and equivalents on Dec. 31. The firm's President and CEO Cameron Reynolds said that during 2019 its existing investors exercising more than $16 million in outstanding warrants to purchase shares of its common stock. The company received an additional $3.3 million in non-dilutive funding, taking its total non-dilutive funding to date, including grants and loans, to more than $7.5 million. Its monthly cash burn was about $1.2 million in 2019.

The firm said it has re-engineered its Nu.Q assays to include a magnetic particle-based assay format, leading to an improvement in analytical performance. The magnetic particle-based assay format has demonstrated an analytical sensitivity up to 20 times higher than its ELISA plate Nu.Q assay format, the firm said.


Abbott’s board this week declared a quarterly common dividend of $.36 per share, payable on May 15 to shareholders of record at the close of business on April 15.  


Bruker’s board of directors has approved a quarterly cash dividend of $.04 per share, payable on March 20 to shareholders of record on March 9. 


Luminex this week declared a quarterly cash dividend of $.09 per share, payable on April 9 to shareholders of record on March 19.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx